Very hard to say how things would shake out competitively if the FDA granted ABT’s request. The most likely outcome, IMO, would be an adverse effect on FoB players (including MNTA/BAX) who intend to rely on the 351(k) pathway and a marginal positive effect on such companies as MRK who intend to rely on the conventional BLA pathway (#msg-75071696).
As previously opined, I don’t give ABT’s CP much of a chance of influencing FDA policy on FoB’s.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.